<SEC-DOCUMENT>0001564590-20-017581.txt : 20200421
<SEC-HEADER>0001564590-20-017581.hdr.sgml : 20200421
<ACCEPTANCE-DATETIME>20200421090243
ACCESSION NUMBER:		0001564590-20-017581
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20200420
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200421
DATE AS OF CHANGE:		20200421

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IRIDEX CORP
		CENTRAL INDEX KEY:			0001006045
		STANDARD INDUSTRIAL CLASSIFICATION:	ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
		IRS NUMBER:				770210467
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1228

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-27598
		FILM NUMBER:		20804081

	BUSINESS ADDRESS:	
		STREET 1:		1212 TERRA BELLA AVE
		CITY:			MOUNTAIN VIEW
		STATE:			CA
		ZIP:			94043
		BUSINESS PHONE:		6509404700

	MAIL ADDRESS:	
		STREET 1:		1212 TERRA BELLA AVENUE
		CITY:			MOUNTAIN VIEW
		STATE:			CA
		ZIP:			94043
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>irix-8k_20200420.htm
<DESCRIPTION>8-K
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
irix-8k_20200420.DOCX.htm
</title>
</head>
<!-- NG Converter v5.0.2.38 -->
<body>

<p style="margin-top:0pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:468pt;;">
<tr>
<td style="width:130.5pt;"></td>
<td style="width:0.9pt;"></td>
<td style="width:24.6pt;"></td>
<td style="width:156pt;"></td>
<td style="width:30pt;"></td>
<td style="width:0.9pt;"></td>
<td style="width:125.1pt;"></td>
</tr>
<tr>
<td colspan="7" valign="top" >
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;;font-size:16pt;letter-spacing:0pt;font-weight:bold;letter-spacing:-0.2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;text-indent:36pt;;">UNITED STATES<br />SECURITIES AND EXCHANGE COMMISSION</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:36pt;;font-size:10pt;font-weight:bold;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Washington, D.C. 20549</p></td>
</tr>
<tr>
<td colspan="7" valign="top" >
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:36pt;;font-weight:bold;font-size:11pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"></p></td>
</tr>
<tr>
<td colspan="7" valign="top" >
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:36pt;;font-size:16pt;letter-spacing:0pt;font-weight:bold;letter-spacing:-0.2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM 8&#8209;K</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:36pt;;font-size:12pt;letter-spacing:0pt;font-weight:bold;letter-spacing:-0.2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CURRENT REPORT</p></td>
</tr>
<tr>
<td colspan="7" valign="top" >
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:36pt;;font-weight:bold;font-size:11pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"></p></td>
</tr>
<tr>
<td colspan="7" valign="middle" >
<p style="margin-top:6pt;text-align:center;margin-bottom:0pt;margin-left:0pt;;text-indent:36pt;;font-size:11pt;letter-spacing:0pt;font-weight:bold;letter-spacing:-0.15pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PURSUANT TO SECTION 13 OR 15(d) OF THE<br />SECURITIES EXCHANGE ACT OF 1934</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:6pt;text-align:center;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:bold;">&nbsp;</p></td>
<td colspan="4" valign="top" >
<p style="margin-top:6pt;text-align:center;margin-bottom:0pt;margin-left:0pt;;text-indent:36pt;;font-size:10pt;letter-spacing:0pt;font-weight:bold;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">April 20, 2020</p></td>
<td colspan="2" valign="top" >
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:bold;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="7" valign="top" >
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:36pt;;letter-spacing:0pt;font-weight:bold;font-size:8pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Date of Report (date of earliest event reported)</p></td>
</tr>
<tr>
<td colspan="7" valign="top" >
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:36pt;;font-weight:bold;font-size:11pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"></p></td>
</tr>
<tr>
<td colspan="7" valign="top" >
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:36pt;;font-size:22pt;letter-spacing:0pt;font-weight:bold;letter-spacing:-0.2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">IRIDEX CORPORATION</p></td>
</tr>
<tr>
<td colspan="7" valign="top" >
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:36pt;;letter-spacing:0pt;font-weight:bold;font-size:8pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of registrant as specified in its charter)</p></td>
</tr>
<tr>
<td colspan="7" valign="top" >
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:36pt;;font-weight:bold;font-size:11pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"></p></td>
</tr>
<tr>
<td colspan="3" valign="top" >
<p style="margin-top:6pt;text-align:center;margin-bottom:0pt;margin-left:0pt;;text-indent:36pt;;font-size:10pt;letter-spacing:0pt;font-weight:bold;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Delaware</p></td>
<td valign="top" >
<p style="margin-top:6pt;text-align:center;margin-bottom:0pt;margin-left:0pt;;text-indent:36pt;;font-size:10pt;letter-spacing:0pt;font-weight:bold;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">0-27598</p></td>
<td colspan="3" valign="top" >
<p style="margin-top:6pt;text-align:center;margin-bottom:0pt;margin-left:0pt;;text-indent:36pt;;font-size:10pt;letter-spacing:0pt;font-weight:bold;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">77-0210467</p></td>
</tr>
<tr>
<td colspan="3" valign="top" >
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:36pt;;letter-spacing:0pt;font-weight:bold;font-size:8pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or other jurisdiction of<br />incorporation or organization)</p></td>
<td valign="top" >
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:36pt;;letter-spacing:0pt;font-weight:bold;font-size:8pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Commission File Number)</p></td>
<td colspan="3" valign="top" >
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:36pt;;letter-spacing:0pt;font-weight:bold;font-size:8pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(I.R.S. Employer<br />Identification Number)</p></td>
</tr>
<tr>
<td colspan="7" valign="top" >
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:36pt;;font-size:10pt;letter-spacing:0pt;font-weight:bold;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1212 Terra Bella Avenue<br />Mountain View, California 94043</p></td>
</tr>
<tr>
<td colspan="7" valign="top" >
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:36pt;;letter-spacing:0pt;font-weight:bold;font-size:8pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of principal executive offices, including zip code)</p></td>
</tr>
<tr style="height:20.25pt;">
<td colspan="2" valign="top" >
<p style="margin-top:6pt;text-align:center;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:bold;">&nbsp;</p></td>
<td colspan="4" valign="top" >
<p style="margin-top:6pt;text-align:center;margin-bottom:0pt;margin-left:0pt;;text-indent:36pt;;font-size:10pt;letter-spacing:0pt;font-weight:bold;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(650) 940-4700</p></td>
<td valign="top" >
<p style="margin-top:6pt;text-align:center;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:bold;">&nbsp;</p></td>
</tr>
<tr style="height:11.65pt;">
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;font-weight:bold;">&nbsp;</p></td>
<td colspan="4" valign="top" >
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:36pt;;font-size:8pt;letter-spacing:0pt;font-weight:bold;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Registrant&#8217;s telephone number, including area code)</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:bold;">&nbsp;</p></td>
</tr>
<tr style="height:4.5pt;">
<td colspan="7" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-weight:bold;">&nbsp;</p></td>
</tr>
<tr style="height:11.65pt;">
<td colspan="7" valign="top" >
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:36pt;;font-size:8pt;letter-spacing:0pt;font-weight:bold;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Former name or former address, if changed since last report)</p></td>
</tr>
<tr>
<td colspan="7" valign="top" >
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:36pt;;font-weight:bold;font-size:11pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"></p></td>
</tr>
<tr>
<td colspan="7" valign="top" >
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:36pt;;font-weight:normal;font-size:10pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </p></td>
</tr>
<tr>
<td colspan="7" valign="top" >
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:22.3pt;;margin-right:0.21%;text-indent:-22.3pt;;font-size:10pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="Check1"></a><font style="font-size:10pt;letter-spacing:-0.1pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><a name="Check1"></a>&#9744;</font><font style="font-weight:bold;"></font>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td>
</tr>
<tr>
<td colspan="7" valign="top" >
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:22.3pt;;margin-right:0.21%;text-indent:-22.3pt;;font-size:10pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;letter-spacing:-0.1pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';">&#9744;</font><font style="font-weight:bold;"></font>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td>
</tr>
<tr>
<td colspan="7" valign="top" >
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:22.3pt;;margin-right:0.21%;text-indent:-22.3pt;;font-size:10pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="Check3"></a><font style="font-size:10pt;letter-spacing:-0.1pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><a name="Check3"></a>&#9744;</font><font style="font-weight:bold;"></font>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td>
</tr>
<tr>
<td colspan="7" valign="top" >
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:22.3pt;;margin-right:0.21%;text-indent:-22.3pt;;font-size:10pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;letter-spacing:-0.1pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';">&#9744;</font>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p></td>
</tr>
<tr>
<td colspan="7" valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;margin-right:0.21%;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="7" valign="top" >
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;margin-right:0.21%;text-indent:0pt;;font-size:10pt;letter-spacing:-0.2pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p></td>
</tr>
<tr>
<td colspan="7" valign="top" >
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;margin-right:0.21%;text-indent:0pt;;font-size:10pt;letter-spacing:0pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company&nbsp;&nbsp;<font style="font-size:11pt;font-family:'Times New Roman';">&#9744;</font><font style="font-size:11pt;"></font></p></td>
</tr>
<tr>
<td colspan="7" valign="top" >
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;margin-right:0.21%;text-indent:0pt;;font-size:10pt;letter-spacing:0pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&nbsp;&nbsp;<font style="font-size:11pt;font-family:'Times New Roman';">&#9744;</font><font style="font-size:11pt;"></font></p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section 12(b) of the Act:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title of Class</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:15%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Trading</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Symbol</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:45%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name of Exchange on Which Registered</p></td>
</tr>
<tr>
<td valign="top"  style="width:38%; border-top:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common Stock, par value $0.01 per share</p></td>
<td valign="bottom"  style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:15%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IRIX</p></td>
<td valign="bottom"  style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:45%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nasdaq Global Market</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU4"></a>&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:0.6%;width:104.74%;">
<tr>
<td style="width:10.17%;"></td>
<td style="width:94.57%;"></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:7.14%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> <font style="font-style:italic;">(d) Appointment of Director</font></p>
<div style="border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-left:0%;margin-right:0%;">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;margin-right:0pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April 20, 2020, Iridex Corporation (the &#8220;Company&#8221;) appointed Doris Engibous to its board of directors (the &#8220;Board&#8221;), effective April 20, 2020 (the &#8220;Effective Date&#8221;). In connection with Ms. Engibous&#8217;s appointment to the Board: 1) the size of the Board was increased from six to seven members as of the Effective Date and 2) Maria Sainz has decided that she will not stand for re-election at the Company&#8217;s 2020 annual meeting of stockholders, but will continue to serve as a member of the Board and the committees she is on until the expiration of her current term ending on the date of the 2020 annual meeting. As a result, Ms. Sainz&#8217;s resignation will be effective immediately prior to the 2020 annual meeting of stockholders.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;margin-right:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;margin-right:0pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ms. Engibous will receive standard compensation available to non-employee members of the Board and committees of the Board and has been granted an option to purchase 15,000 shares of the Company&#8217;s common stock which vests in equal monthly installments over four years following the effective date of the grant.&nbsp;&nbsp;In addition, it is expected that Ms. Engibous will execute the Company&#8217;s standard form of indemnification agreement.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;margin-right:0pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ms. Engibous has served as a consultant and advisor to medical technology companies and executives since 2010. Since 2019, Ms. Engibous has served on the board of directors of Imricor Medical Systems Inc., a pioneer and leader in developing MRI-compatible products for cardiac catheter ablation procedures. From 2014, Ms. Engibous has also served on the board of directors of GI Supply Inc., a family-owned provider of innovative medical products. From 2004 to 2018, Ms. Engibous served on the board of directors of Natus Medical Inc., a $500 million provider of leading healthcare products. From 2004 to 2010, she served as President and CEO of Hemosphere Inc., an early stage, venture capital funded medical technology company, prior to its acquisition by CryoLife Inc. Prior to 2004, Ms. Engibous served from 2000 through 2003 as President of Nellcor, a business of Tyco Healthcare Group/Tyco International Ltd. From 1986 through 2000, Ms. Engibous served in several executive capacities at Nellcor and its successors Nellcor Puritan Bennett Inc. and Mallinckrodt Inc., including as vice president, general manager and global business leader and senior director of marketing, and was responsible for the integration of Nellcor into Mallinckrodt and later Tyco Healthcare. Ms. Engibous served on the board of directors of the National Kidney Foundation serving Minnesota, the Dakotas and Iowa from 2006 to 2010. She holds a Bachelor of Science degree in Chemical Engineering from the University of Michigan. </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;margin-right:0pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ms. Engibous is distinguished by her technical background in Chemical Engineering, coupled with strong operational experience in manufacturing, regulatory affairs, quality assurance and marketing. She brings to the Iridex Board over 30 years of experience in the medical device industry, including knowledge of organizational and operational management, financial expertise, marketing, R&amp;D, human resources and integration experience relevant to a public company in the healthcare industry. </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;margin-right:0pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is no arrangement or understanding between Ms. Engibous and any other person pursuant to which Ms. Engibous was elected as a director of the Company. There are no family relationships between Ms. Engibous and any director or executive officer of the Company, and, other than as described above, no transactions involving Ms. Engibous that would require disclosure under Item 404(a) of Regulation S-K.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;margin-right:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;margin-right:0pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On the Effective Date, the Board also modified the composition of the Compensation Committee of the Board and Nominating and Governance Committee of the Board to consist of the following directors: </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;margin-right:0pt;text-indent:7.14%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;margin-right:0pt;text-indent:7.14%;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;<font style="font-family:Times New Roman;">Compensation Committee: Doris Engibous (Chair), Robert Grove, Ph.D., Kenneth E. Ludlum, Maria Sainz and Scott Shuda.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;margin-right:0pt;text-indent:7.14%;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;<font style="font-family:Times New Roman;">Nominating and Governance Committee: Robert A. Gunst (Chair), Doris Engibous, Kenneth E. Ludlum and Maria Sainz. </font></p></div>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0%;white-space:nowrap">
<p style="margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">-2</a>-</p></td></tr></table></div>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:7.14%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:14.29%;text-indent:-14.29%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:14.29%;text-indent:-14.29%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:14.29%;text-indent:-14.29%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:14.29%;white-space:nowrap">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item 9.01.</font></p></td>
<td valign="top">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>Financial Statements and Exhibits. </p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d) Exhibits </p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit<br />No.</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;width:89%; border-bottom:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;width:90%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;width:10%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1*</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;width:89%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1006045/000156459016021155/irix-ex101_6.htm"><font style="text-decoration:underline;">Form of Indemnification Agreement, between the Company and certain of its directors and executive officers.</font></a></p></td>
</tr>
<tr>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;width:10%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.1</p></td>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;width:89%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="irix-ex991_6.htm"><font style="text-decoration:underline;">Press Release dated April 21, 2020.</font></a></p></td>
</tr>
</table></div>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">* Incorporated by reference to the Exhibits filed with the Registrant&#8217;s Report on Form 8-K on July 11, 2016<font style="font-family:Arial;">.</font></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.14%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:7.14%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a>SIGNATURES </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:41.65%;">
<tr>
<td style="width:4.06%;"></td>
<td style="width:1.74%;"></td>
<td style="width:35.85%;"></td>
</tr>
<tr>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;text-align:left;">&nbsp;</p></td>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;text-align:left;">&nbsp;</p></td>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">IRIDEX CORPORATION</p></td>
</tr>
<tr style="height:12pt;">
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:1pt;margin-top:0pt;border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ David I. Bruce</p></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">David I. Bruce</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: April 21, 2020 </p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0%;white-space:nowrap">
<p style="margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">-3</a>-</p></td></tr></table></div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>irix-ex991_6.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
irix-ex991_6.htm
</title>
</head>
<!-- NG Converter v5.0.2.38 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk14952995"></a><img src="gb4ivtxo24ty000001.jpg" title="" alt="" style="width:96px;height:77px;"></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:14pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:14pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">IRIDEX Announces the Appointment of Doris Engibous to its Board of Directors </p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Mountain View, Calif. April 21, 2020<font style="font-weight:normal;"> -- IRIDEX Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the appointment of Doris Engibous to its board of directors effective April 20, 2020. The Company will also nominate Ms. Engibous for re-election to the board at its 2020 Annual Meeting of Stockholders.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;I am delighted to welcome Doris to our board of directors,&#8221; said Robert Gunst, chairman of the board of IRIDEX. &#8220;Doris has an ideal background given her extensive experience leading and guiding successful medical technology companies. Her skills are very complementary to our team and we are confident she can help guide the Company to greater business success and increased shareholder value.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#333333;font-size:12pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On her appointment, Ms. Engibous commented, &#8220;I am honored to join the IRIDEX board as they advance commercialization and expand their market share with a unique laser-based approach to glaucoma treatment. I look forward to contributing my expertise to the Company&#8217;s commercialization strategy to further IRIDEX's position in treating sight-threatening diseases.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#333333;font-size:12pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maria Sainz has notified the IRIDEX board that she will not stand for re-election at the Company&#8217;s 2020 Annual Shareholder Meeting. Ms. Sainz has served on the IRIDEX board since April 2018. The entire IRIDEX team greatly appreciates her service and insights, which have contributed significant value to shareholders and the growth of the business. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#333333;font-size:12pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Following the retirement of Ms. Sainz, the Company&#8217;s board will be composed of six directors. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#333333;font-size:12pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">About Doris Engibous</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#333333;font-size:12pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ms. Engibous has been an independent consultant and advisor to medical technology companies and executives since 2010. She currently serves on the board of directors of Imricor Medical Systems Inc., a pioneer and leader in developing MRI-compatible products for cardiac catheter ablation procedures and GI Supply Inc., a family-owned provider of innovative medical products. Previously, Ms. Engibous served on the board of directors of Natus Medical Inc., a $500 million leading provider of healthcare products, as well as the National Kidney Foundation serving Minnesota, the Dakotas and Iowa. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#333333;font-size:12pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a>From 2004 to 2010, Ms. Engibous served as President and CEO of Hemosphere Inc., an early stage, venture capital funded medical technology company, prior to its acquisition by CryoLife </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;color:#333333;font-size:12pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#333333;font-size:12pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inc. Prior to 2004, Ms. Engibous served 18 years in several executive capacities at Nellcor and its successors Nellcor Puritan Bennett Inc., Mallinckrodt Inc., and Tyco Healthcare including President of Nellcor, and was responsible for the integration of Nellcor into Mallinckrodt and later Tyco Healthcare. She holds a Bachelor of Science degree in Chemical Engineering from the University of Michigan.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#333333;font-size:12pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">About&#160;IRIDEX</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#333333;font-size:12pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IRIDEX is a worldwide leader in developing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company&#8217;s proprietary MicroPulse&#174; technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions.&#160;IRIDEX&#8217;s current product line is used for the treatment of glaucoma, diabetic macular edema (DME) and other retinal diseases. IRIDEX products are sold in&#160;the United States and Germany through a direct sales force and in more than 100 countries through a network of independent distributors. <font style="color:#000000;">For further information, visit the IRIDEX website at </font><font style="text-decoration:underline;color:#000000;">http://www.iridex.com/</font><font style="color:#000000;">.</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Investor Relations Contact<font style="font-weight:normal;"><br />Leigh Salvo<br />(415) 937-5404<br /></font><font style="text-decoration:underline;font-weight:normal;">investors@iridex.com</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Media Contact<font style="font-weight:normal;"><br />Jamie Hall <br />Pascale Communications, LLC.<br />(724) 417-0167<br /></font><font style="text-decoration:underline;font-weight:normal;">pr@iridex.com</font></p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>gb4ivtxo24ty000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gb4ivtxo24ty000001.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" "P -P# 2(  A$! Q$!_\0
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MP(RHL".2(A\S$X.3QG[HKDS"IEM/7"3;B_LR6WS.[+*>:5(6QT%&:M[T7O\
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M5?\ A+M_\<H_XBA/^"4'_11/%7'7_BEV_P#CE?S(^#K:#4?%VE6-XBR0S:G
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MI7_*-/\ : _[(SXE_P#39<5_'(?NB@(G]L'[.7_)OG@7_L3=+_\ 22*O(?\
M@L'_ ,HN/C]_V2G6?_25Z]>_9R_Y-\\"_P#8FZ7_ .DD5>0_\%@_^47'Q^_[
M)3K/_I*]!)_'Y7]N'P=?/PG\+@G_ )EVR_\ 1"5_$?7[.?M!_L1_\'!?[,O[
M*TO[1NC?MX:MXJTC1]'M[V;0/#.N7KWL%D8U)D2-HP&"+MRJDD#)' Q05(_<
MCXM_&CX6_ SP9??$#XO^/M+\.:+I]K+<75]JEXL*+&BEFQG[QP#\JY)/ %?Q
M\_M\_M"V'[77[97Q(_:/TBSN+6R\8^++G4--M;P@R1VS-B%6QQD(%&,\=,FL
M_P"(?[4OQG_:6\9Z;=?M/?'/Q=XAL)-2B_M*YO-2>ZD@@+*DKQ1R-L+[!PO
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M' "R*2<'C\VU_P"#RKQ,XY_8&L>O_10G_P#D*OD?]@3]H+Q_^UE_P5B\5?\
M!27X\:'+KO\ PKCPYX@^)VO:99P*\<4&FV,IM+*,N<1*KFVBB<ABK*C')R:
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8]CCQ<LFW]XJ:]:LH;N <#(]\"@GE/__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
